Sumatriptan Statdose

ApprovedSmall molecule

DDiamond Headache Clinic

Sumatriptan Statdose is one of 24 small molecule programs targeting Cluster headache. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cluster HeadacheActive, not recruiting

Cluster HeadacheApproved

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Cluster Headache

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Topamax

WWim Janssens

Approved

1 3

Emgality

Eli Lilly

Phase 3

3 4

Ajovy

Teva

Phase 3

3 5

Vyepti

Lundbeck

Phase 3

2 6

Xyrem

Jazz Pharmaceuticals

Phase 3

1 7

Rituxan

Roche

Phase 3

—8

Botox

RRevance Therapeutics, Inc.

Phase 3

3 9

Calan

VVal Adams

Phase 3

1 10

Sumatriptan Succinate

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cluster headache1 trial

Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

Unknown status·DDiamond Headache Clinic·Phase 4·NCT00399243·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sumatriptan Statdose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sumatriptan Statdose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sumatriptan Statdose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Diamond Headache Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: DDiamond Headache Clinic

Sumatriptan Statdose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cluster headache1 trial

References

Drug Info

Quick Facts

Related News